New research published in the journal Frontiers in Psychology surveyed more than 1,000 people about their sleep and eating habits. It found that those who had worse symptoms of lactose intolerance also had more intense nightmares. You know, it's interesting.It was a thousand participants in this study and they looked at it and they correlated a couple things. One, how they slept, what happened when they slept as in their dreams and what they ate before they went to sleep. And like you mentioned, you know, 5 ...

Important Milestone Clears the Way for Millions of Medicare Beneficiaries with Sleep Apnea to Access Vivos’ Patented and FDA-Cleared Oral Appliance TreatmentLITTLETON, Colo., July 01, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced that its VidaSleep™ oral appliance, featuring Vivos’ patented and U.S. Food and Drug Administration (FD ...

If you have ever found yourself tossing and turning and counting sheep unable to sleep, I can tell you from firsthand experience, you are not alone. In her new piece for The Atlantic titled American Insomnia, staff writer Jennifer Senior writes in part, "The cadences of modern life have proved enimical to sleep. For white collar professionals, it's hard to imagine a job without the woodpecker incursions of email or weekend and late night work. It's hard to imagine children assuing social media when it's how ...

Struggling with the long days and want to get your sleep schedule back on track? Then let in some early morning light. Bloomberg Prognosis explains how to ease circadian rhythm confusion. https://t.co/MTGu82bnGq ...

Important Study Shows Vivos Technology to be a Safe and Highly Effective, Non-Surgical Alternative to Surgical Removal of Tonsils and Adenoids in ChildrenLITTLETON, Colo., June 26, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced that the European Journal of Pediatrics has published the results of a groundbreaking multicenter clinical trial evidencing positive resul ...

Hi everyone. Have you ever been in a situation where you came home from work, very busy day, and you were quite tired, maybe even exhausted, and so you decided to go to bed just a little bit earlier? You're lying in bed and after 30 minutes or so you suddenly realize I am not falling asleep and then this feeling creeps up on you a jolt of anxiety, frustration and you start to think about all the reasons why you should fall asleep right now. Maybe you have an important meeting, a deadline, an exam, a TED tal ...

Brody Barnes considers how the school system as currently designed negatively affects students' health and sleeping habits due to schedule, overworking, expectations of home life, and extra-curricular activities. Brody Barnes has applied himself to studying Biology and the life sciences, studious in his effort towards working as a Scientific Reseacher. A passionate advocate for improving the lively hood of all people, he argues for standing up to authority without trampling over the powerless. This talk was ...

Summary of Inspire Medical Systems (INSP) 2025 Conference Call Company Overview - **Company**: Inspire Medical Systems (INSP) - **Event**: 2025 Conference Call - **Date**: June 13, 2025 Key Points Industry and Market Dynamics - Discussion focused on the **Obstructive Sleep Apnea (OSA)** market and the competitive landscape surrounding it [2][10] - Emphasis on the **Inspire five** launch and its implications for the OSA treatment market [2][10] Inspire Five Launch - **Inspire five** features a **20% reduction in implant time** and improved sensing technology integrated into the neurostimulator [10][26] - The new device incorporates an **accelerometer** for respiration sensing, eliminating the need for a separate pressure sensing lead, thus simplifying the implant procedure [14][21] - The device allows for **Bluetooth communication** with a patient app and integrates with **SleepSync**, a cloud-based patient management system [11][12] Clinical Data and Performance - Clinical trials showed that **Inspire five** improved **inspiratory phase overlap** from **78% to 83%**, enhancing treatment effectiveness [22][24] - A study in Singapore indicated that the average nightly usage post-implant was **six hours**, demonstrating strong patient adherence [27] - The **St. Luke's Health** study reported over **80% success rate** in positional sleep apnea, indicating improved efficacy compared to previous trials [31][32] Surgeon Feedback and Adoption - Surgeons reported positive feedback regarding the ease of implantation without the pressure sensing lead, leading to reduced operating room (OR) time [41][42] - The transition to **Inspire five** is expected to increase the number of procedures performed by surgeons due to improved efficiency [64][70] Financial and Market Outlook - The company anticipates continued growth in adoption of Inspire therapy, with a focus on penetrating the **single-digit percentage** of the overall target market [38][39] - The **2025 guidance** includes expectations for increased capacity and productivity from surgeons, despite some anticipated competitive trials [82][83] Competitive Landscape - The emergence of **GLP-1 medications** for weight management in sleep apnea patients was discussed, with the potential for these treatments to complement Inspire therapy [98][104] - The company is monitoring the impact of GLP-1 on patient demand and treatment eligibility, noting that Inspire therapy remains effective for patients with tongue-based obstruction [100][103] Future Developments - Inspire is already working on **Inspire six**, which aims to enhance therapy adherence by detecting sleep states and automatically adjusting stimulation [90][91] - The integration of **SleepSync** with Inspire five is expected to facilitate better patient management and data collection for future improvements [92] Conclusion - Inspire Medical Systems is positioned for growth with the launch of Inspire five, leveraging advanced technology to improve patient outcomes and streamline surgical procedures. The company is optimistic about its market penetration and future innovations while navigating competitive pressures from emerging therapies.

Group 1 - Tonix Pharmaceuticals is a clinical-stage biotechnology firm focused on developing TNX-102 SL, a compound aimed at improving sleep quality in fibromyalgia patients [1] - The FDA is currently reviewing TNX-102 SL, with a Prescription Drug User Fee Act (PDUFA) date set for August 15, 2025 [1] - The company aims to bridge the gap between scientific advancements and financial strategies in the healthcare sector, assisting clients in uncovering hidden value and assessing risks [1]

Over $11 million in new financing secured by Vivos, including a senior secured loan from Streeterville Capital and an equity private placement by existing investor New Seneca Partners LITTLETON, Colo., June 11, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leader in delivering and promoting sleep wellness and health through its proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced the closing of its acquisition of the operati ...